EBITDA Slips to ₹1,930 billion, Margin Falls to 24.1% in Q1

In its first‑quarter financial filing, Jaidis Lifesciences disclosed that earnings before interest, tax, depreciation and amortisation (EBITDA) fell to ₹1,930 crore, a 7.6% decline from the ₹2,089 crore recorded in the same quarter last fiscal year. The reduction pushed the EBITDA margin to 24.1%, down from 31.8% previously.

The dip in margin came despite a 22% increase in revenue to ₹8,017 crore, driven by higher sales of generic formulations, active pharmaceutical ingredients and vaccine products across its global footprint.

Net profit also contracted sharply, slipping 35.9% to ₹940 crore year‑on‑year. The company attributed the pressure to rising input costs and intensified competition in key therapeutic segments.

Investors reacted with a modest rally; the stock traded at ₹1,126, up ₹7 (0.63%) after the results were announced. Over the last five sessions the share price rose 1.41% (₹15.70), while the month‑long trend showed a slight dip of 0.52% (₹5.90). Over six months the stock is up 25.43% (₹228.40) and has gained 23.20% (₹212.25) since the beginning of the year.